Related Experiment Videos
Short- and long-acting synthetic pentasaccharides
1Department of Vascular Medicine, Academic Medical Centre, Amsterdam, The Netherlands. m.m.koopman.uva.nl
Journal of Internal Medicine
|September 17, 2003
Summary
New pentasaccharides offer targeted antithrombotic therapy by specifically inhibiting activated coagulation factor X (FXa). These agents, like Fondaparinux and Idraparinux, show promise in preventing and treating thromboembolic events and managing related cardiovascular conditions.
Area of Science:
- Pharmacology
- Hematology
- Drug Development
Background:
- Activated coagulation factor X (FXa) is a key target for antithrombotic therapies due to its central role in the coagulation cascade.
- Current anticoagulants often inhibit both FXa and thrombin, leading to potential side effects.
- Pentasaccharides represent a novel class of antithrombotics with specific FXa inhibition and no activity against FIIa (thrombin).
Purpose of the Study:
- To review the development and clinical evaluation of pentasaccharide antithrombotic agents.
- To highlight the efficacy and safety profiles of Fondaparinux and Idraparinux in various thromboembolic conditions.
Main Methods:
- Review of clinical trial data for Fondaparinux and Idraparinux.
- Analysis of studies concerning venous thromboembolism prophylaxis and treatment.
- Examination of studies in acute coronary syndromes, deep-vein thrombosis, and atrial fibrillation.
Main Results:
- Fondaparinux, a short-acting pentasaccharide, has undergone extensive Phase II and III trials for venous thromboembolism.
- Idraparinux, a long-acting pentasaccharide, has been studied in deep-vein thrombosis and is planned for further Phase III trials.
- Pentasaccharides demonstrate targeted FXa inhibition, offering a distinct therapeutic approach.
Conclusions:
- Pentasaccharides are a promising new class of antithrombotic drugs.
- Specific FXa inhibition by pentasaccharides provides a targeted approach to anticoagulation.
- Fondaparinux and Idraparinux show potential in managing a range of thromboembolic disorders and related cardiovascular conditions.